Lotte Biologics invests in S.Korean bio-venture Pinotbio

The two firms to collaborate in the development and production of ADC platform technology

Lotte Biologics invests in S.Korean bio-venture Pinotbio
Ji-Hyun Lee 1
2023-04-21 18:12:12 bluesky@hankyung.com
Bio & Pharma


South Korea’s Lotte Biologics Co. said on Friday that it has made an equity investment in Pinotbio, Inc. for the development of antibody-drug conjugate (ADC) platforms.

ADC is a type of biopharmaceutical in which antibodies that selectively attack antigens are combined with drugs that have therapeutic effects through a linker.

Pinotbio possesses the necessary drugs and linker technology for the development of ADC anti-cancer agents.

Through this investment, Lotte Biologics plans to establish a strategic business partnership with PinotBio and collaborate in the development and production of ADC platform technology. The companies also plan to explore ADC contract development service partnerships.

Furthermore, the investment marks the beginning of Lotte Biologics' Bio-Venture Initiative. The company aims to provide facilities and technology development cooperation opportunities for biotechnology ventures in the antibody pharmaceutical production factory that they plan to build domestically.

"Through cooperation with PinotBio, we plan to accelerate the expansion of our ADC CDMO business," said Lee, Won-Jik, the CEO of Lotte Biologics.

Write to Ji-Hyun Lee at bluesky@hankyung.com

Lotte Biologics to invest additional $48 mn in US plant

Lotte Biologics to invest additional $48 mn in US plant

South Korea’s Lotte Biologics Co. held a plaque ceremony on Monday to commemorate the acquisition of a pharmaceutical production plant from Bristol Myers Squibb in Syracuse, New York, at the end of last year.Lotte Biologics plans to invest approximately $48 million in the Syracuse plant

Lotte Biologics, Excellgene to collaborate on CDO biz

Lotte Biologics, Excellgene to collaborate on CDO biz

Lotte Biologics, South Korea's biopharmaceutical contract development and manufacturing organization (CDMO) company, announced on Sunday that it has entered into a memorandum of understanding (MOU) with Swiss-based cell line development company Excellgene for collaboration on contract developm

(* comment hide *}